European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT)
Abstract Hereditary haemorrhagic telangiectasia (HHT) is a multisystemic vascular dysplasia that leads to nosebleeds, anaemia due to blood loss, and arteriovenous malformations (AVMs) in organs such as the lungs, liver and brain. HHT is estimated to affect 85,000 European citizens, but most health c...
Main Authors: | Claire L. Shovlin, Elisabetta Buscarini, Anette D. Kjeldsen, Hans Jurgen Mager, Carlo Sabba, Freya Droege, Urban Geisthoff, Sara Ugolini, Sophie Dupuis-Girod |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-08-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-018-0850-2 |
Similar Items
-
Recent insight into the prevalence, etiology, and outcome of epistaxis in a university hospital in Saudi Arabia
by: Sami E Alharethy
Published: (2019-01-01) -
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial
by: Sophie Dupuis-Girod, et al.
Published: (2020-04-01) -
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia
by: C. L. Shovlin, et al.
Published: (2019-08-01) -
The Endovascular Treatment of Epistaxis
by: Simon Nicolay, et al.
Published: (2015-12-01) -
Life-threatening anaemia in patient with hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)
by: Mikołajczyk-Solińska Melania, et al.
Published: (2020-03-01)